Biotechnology

Inovio Pharma

Inovio Pharma released FY2026 Q1 earnings on May 13 After-Market (EST), actual revenue USD 0 (forecast USD 250K), actual EPS USD -0.2848 (forecast USD -0.35)

Inovio Pharma to Release FY2026 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 250K, EPS USD -0.35

Inovio Pharma released FY2025 earnings on March 12 After-Market EST, actual revenue USD 65.34 K (forecast USD 88.33 K), actual EPS USD -1.8117 (forecast USD -2.225)

Inovio Pharma released FY2025 Q4 earnings on March 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD 0.0606 (forecast USD -0.358)

Inovio Pharma to Release FY2025 Q4 Earnings on March 12 After-Market (EST), Forecast EPS -0.358 USD

CanSino and Inovio Partner to Evaluate Efficacy in Glioblastoma Treatment

Inovio Pharmaceuticals Set to Raise About $26.5 Million Through Public Offering of 13.158 Million Shares

Inovio Pharma released FY2025 Q3 earnings on November 10 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8721 (forecast USD -0.4233)

Inovio Pharma released FY2025 9 Months Earnings on November 10 After-Market EST, Actual Revenue: USD 65.34K, Actual EPS: USD -1.1157

INOVIO Completes Rolling Submission for INO-3107 Biologics License Application

Inovio Pharma to Release FY2025 Q3 Earnings on November 10 After-Market EST, Forecast EPS -0.4233 USD

INOVIO to Present INO-3107 Data and Next-Generation DNA Drug Technologies at Upcoming Scientific Conferences

Inovio Pharmaceuticals Reports Exceeding Expected Quarterly EPS

Inovio Pharma released FY2025 Semi-Annual earnings on August 12 After-Market EST, actual revenue USD 65.34 K, actual EPS USD -1.1159

Inovio Pharma released FY2025 Q2 earnings on August 12 After-Market EST: Actual Revenue USD 0 (Forecast USD 8.33 K), Actual EPS USD -0.6057 (Forecast USD -0.61)

Inovio Pharmaceuticals Expects Q2 EPS Loss of 61 Cents

Inovio Pharma to Release FY2025 Q2 Earnings on August 12 After-Market EST, Forecast Revenue USD 8.33K, EPS USD -0.61

Inovio Pharmaceuticals Reports Q2 2025 Earnings

Inovio Pharmaceuticals Rated as Outperform by Analysts

Inovio Pharmaceuticals to Speak at Orphan Drug Summit on Next-Gen DNA Medicine

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IBBQ

LABD

LABU

Inovio Pharmaceuticals Inc. (INO) shares fell 6.15% to $1.22 on Monday, marking the second consecutive day of losses. The stock is now 59.05% below its 52-week high of $2.98. In contrast, competitors like Johnson & Johnson and Pfizer remained stable, while the overall market showed mixed results with the Dow up 0.32% and NASDAQ down 0.51%. Trading volume was 5.3 million, surpassing the 50-day average of 2.7 million.

MarketWatch Automated

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Dow Jones Industrial Average

NASDAQ Composite Index

Johnson & Johnson

Pfizer

Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

SBIO

Inovio Pharmaceuticals Inc. (INO) shares fell 4.41% to $1.30 on Friday, underperforming against competitors like Johnson & Johnson and Pfizer. The NASDAQ Composite Index dropped 1.54%, while Inovio's stock remains 56.36% below its 52-week high of $2.98. Trading volume was 1.9 million, below the 50-day average of 2.7 million.

ALPS Medical Breakthrough

Inovio Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Inovio Pharmaceuticals Inc. (INO) shares rose 1.49% to $1.36 on a positive trading day, breaking a three-day losing streak. The NASDAQ Composite Index increased by 0.88%, while the Dow Jones Industrial Average rose by 0.75%. Inovio's stock remains 54.35% below its 52-week high of $2.98. Competitors had mixed results, with Johnson & Johnson up 0.16%, Statera Biopharma unchanged, and Pfizer down 0.81%. Trading volume was 2.5 million, below the 50-day average of 2.6 million.

Factset Research

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | INO Stock News

StockTitan

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | INO Stock News

Inovio Pharmaceuticals Inc. (INO) shares fell 1.40% to $1.41 on Tuesday, marking the second consecutive day of losses. The stock is currently 52.67% below its 52-week high of $2.98. In comparison, Johnson & Johnson (JNJ) rose 1.28%, while Pfizer Inc. (PFE) increased by 0.23%. The overall market showed mixed results, with the Dow Jones up 0.11% and NASDAQ down 0.71%. Trading volume for Inovio was 3.0 million, surpassing its 50-day average of 2.5 million.

Inovio Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Earnings Watch

Inovio Pharma | 8-K: FY2026 Q1 Revenue: USD 0

Inovio Pharma | 10-Q: FY2026 Q1 Revenue: USD 0

Inovio Pharma(INO.US)

Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Inovio Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | INO Stock News

Inovio Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Inovio Pharma | 8-K: FY2026 Q1 Revenue: USD 0

Inovio Pharma | 10-Q: FY2026 Q1 Revenue: USD 0